Results 21 to 30 of about 46,312 (227)

Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection

Frontiers in Pharmacology, 2021
Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin, Shin-Yi Lin, Yu-Fong Peng, Chih-Fen Huang, Chih-Fen Huang, Ching-Hua Kuo, Sung-Chun Tang, Jiann-Shing Jeng   +7 more
doaj   +1 more source

Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]

, 2015
© Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A, Inoue, Nobutaka, Iwata, Sachiyo, Otsui, Kazunori, Ozawa, Toru, Suzuki, Atsushi, Takei, Asumi, Yamamoto, Junichiro, Yoshioka, Takayuki   +8 more
core   +2 more sources

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Abruscato, Mario Giovanni Rosario, Baas, Horst, Hövelmann, Susanne, Pfeilschifter, Waltraud   +3 more
core   +2 more sources

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

New England Journal of Medicine, 2019
Background Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source.
H. Diener, R. Sacco, D. Easton, C. Granger, R. Bernstein, S. Uchiyama, J. Kreuzer, Lisa Cronin, Daniel Cotton, Claudia Grauer, M. Brueckmann, M. Chernyatina, G. Donnan, J. Ferro, M. Grond, B. Kallmünzer, J. Krupiński, Byung‐Chul Lee, R. Lemmens, J. Masjuán, M. Odinak, J. Saver, P. Schellinger, D. Toni, K. Toyoda   +24 more
semanticscholar   +1 more source

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2015
Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD   +14 more
doaj   +1 more source

Idarucizumab for Dabigatran Reversal.

New England Journal of Medicine, 2015
BACKGROUND Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.
C. Pollack, P. Reilly, J. Eikelboom, S. Glund, P. Verhamme, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, P. Kamphuisen, J. Kreuzer, J. Levy, F. Sellke, J. Stangier, T. Steiner, Bushi Wang, C. Kam, J. Weitz   +17 more
semanticscholar   +1 more source

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]

, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin, Farag, Mohamed, Gorog, Diana A, Khan, Arif, Niespialowska-Steuden, Maria, Okafor, Osita, Srinivasan, Manivannan, Sullivan, Keith, Wellsted, David   +8 more
core   +2 more sources

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis

JAMA Neurology, 2019
Key Points Question Is dabigatran etexilate or dose-adjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis? Findings In this exploratory randomized, open-label
J. Ferro, J. Coutinho, F. Dentali, A. Kobayashi, A. Alasheev, P. Canhão, D. Karpov, S. Nagel, Laura Posthuma, J. Roriz, Jorge Caria, Mandy Fräßdorf, H. Huisman, P. Reilly, H. Diener   +14 more
semanticscholar   +1 more source

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study

European Heart Journal - Cardiovascular Pharmacotherapy, 2020
Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and apixaban in routine clinical practice.
O. Rutherford, C. Jonasson, W. Ghanima, F. Söderdahl, S. Halvorsen   +4 more
semanticscholar   +1 more source